重要日期

  会议日期

       2018年10月19-22日

  摘要截止日期:

       2018年7月31日前

  全文提交日期:

       2018年10月18日前

  网上注册日期:

       2018年10月19日前

  现场报到日期:

       2018年10月19日 

您的位置: 首页 > 会议动态 > 正文

L. James Lee

The Ohio State University

更新时间:2018/7/24 8:50:37

L. James Lee

       Dr. Lee is the Helen C. Kurtz Professor of Chemical and Biomolecular Engineering at The Ohio State University (OSU). He founded and serves as the Director of NSF Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymer Biomedical Devices (CANPBD) at OSU. He received a BS degree in chemical engineering from National Taiwan University and a Ph.D. degree in chemical engineering from University of Minnesota. Before joining OSU in 1982, he worked as a research scientist at General Tire and Rubber Company for 3 years. His research interest includes BioMEMS/NEMS, micro-/nanofabrication, and polymer and composite materials. He has more than 400 refereed journal publications, 30 patents and patent applications, and 14 book chapters. He was elected as the Fellow of American Institute for Medical and Biological Engineering in 2006. Dr. Lee received the 2008 Malcolm E. Pruitt Award from Council of Chemical Research, 2010 International Award from the Society of Plastic Engineers, and 2016 Lifetime Achievement Award from the Society of Advanced Molding Technology.
       报告题目:NANOPORATED CELL TRANSFECTION AND VESICLE SECRETION FOR NUCLEIC ACID DELIVERY -Cancer therapy, Immune disease treatment, and Regenerative medicine
       报告摘要:Nucleic acid therapeutics including small interfering RNA (siRNA), microRNA (miRNA), microRNA antagonists (antagomiRs), antisense oligonucleotides, messenger RNA (mRNA), and DNA plasmids have great potential for disease treatment. However, a major limiting factor is the ability to deliver well-defined amounts of these relatively large and negatively charged molecules into target tissues and cells. A variety of cell transfection techniques have been developed for in vivo gene delivery, including viral vectors and chemical methods (e.g. liposomal and polymeric nanoparticles). But they suffer from severe immunogenicity, poor efficacy, and/or high cost. Recently, cell-secreted vesicles that encapsulate genetic and proteomic materials have emerged as promising therapeutic agents However, only a few cell types such as multipotent stem cells are found to secret high numbers of exosomes that exhibit immunosuppressive activity. Here we show the development of a new technology platform, nanochannel electroporation (NEP) for highly effective cell transfection and vesicle secretion. The potential of those transfected cells and their secreted vesicles is demonstrated in several frontier medical fields including non-viral generation of induced neurons (iNs) for stroke recovery and induced endothelial cells (iECs) for wound healing, therapeutic neutrophils for targeted rheumatoid arthritis (RA) treatment, and therapeutic exosomes for glioblastoma multiforme (GBM) treatment.